292 related articles for article (PubMed ID: 25523507)
1. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
3. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
[TBL] [Abstract][Full Text] [Related]
4. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
[TBL] [Abstract][Full Text] [Related]
5. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia.
Abd El-Lateef AE; Ismail MM; Almohammadi M; Gawaly AM
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):92-98. PubMed ID: 34933728
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
[TBL] [Abstract][Full Text] [Related]
11. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
16. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
19. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
[TBL] [Abstract][Full Text] [Related]
20. The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
Chen X; Tian C; Hao Z; Pan L; Hong M; Wei W; Muyey DM; Wang H; Chen X
Cancer Med; 2023 May; 12(9):10340-10350. PubMed ID: 36912186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
